These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 1509294

  • 21. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia.
    Champlin R, Jansen J, Ho W, Gajewski J, Nimer S, Lee K, Territo M, Winston D, Tricot G, Reichert T.
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1695-6. PubMed ID: 1899162
    [No Abstract] [Full Text] [Related]

  • 22. T cell depletion in bone marrow transplantation for leukemia: current results and future directions.
    Butturini A, Gale RP.
    Bone Marrow Transplant; 1988 May; 3(3):185-92. PubMed ID: 3048485
    [Abstract] [Full Text] [Related]

  • 23. Transfusion effect on graft-versus-host disease and leukemic relapse in HLA-matched bone marrow transplantation.
    de Gast GC, Beatty PG, Amos D, Sullivan K, Anderson JE, Thomas ED, Hansen JA.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2700. PubMed ID: 3274581
    [No Abstract] [Full Text] [Related]

  • 24. Selective depletion of CD8 positive T-lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation.
    Champlin R, Gajewski J, Feig S, Giorgi J, Lyddane N, Lee K, Schmidt I, Winston D, Ho W, Reichert T.
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2947-8. PubMed ID: 2495694
    [No Abstract] [Full Text] [Related]

  • 25. The clinical use of elutriation and positive stem cell selection columns to engineer the lymphocyte and stem cell composition of the allograft.
    Noga SJ, Davis J, Schepers K, Eby L, Berenson RJ.
    Prog Clin Biol Res; 1994 Feb; 389():317-24. PubMed ID: 7535437
    [No Abstract] [Full Text] [Related]

  • 26. Lymphocyte depletion in bone marrow transplantation: will modulation of graft-versus-host disease prove to be superior to prevention?
    Noga SJ, Hess AD.
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):28-33. PubMed ID: 8211214
    [Abstract] [Full Text] [Related]

  • 27. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
    Barrett AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E, Dunbar C, Cottler-Fox M, Phang S, Carter C, Okunnieff P, Young NS, Read EJ.
    Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Bone marrow transplantation in Basel: single center experience from 1973 to 1989.
    Speck B, Nissen C, Tichelli A, Roth J, Dazzi H, Stebler CH, Wernli M, Signer E, Gratwohl A.
    Clin Transpl; 1989 Mar; ():115-22. PubMed ID: 2487556
    [Abstract] [Full Text] [Related]

  • 30. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S.
    Clin Transpl; 1996 Mar; ():281-90. PubMed ID: 9286578
    [Abstract] [Full Text] [Related]

  • 31. Graft-versus-leukaemia after bone marrow transplantation.
    Barret AJ.
    Pediatr Med Chir; 1991 Mar; 13(1):9-13. PubMed ID: 2052462
    [No Abstract] [Full Text] [Related]

  • 32. Graft versus host disease.
    Gordon-Smith EC.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989 Mar; 116(3-4):413-9. PubMed ID: 2480283
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. T-cell depletion in unrelated bone marrow transplantation.
    Tricot G.
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):26-31; discussion 31-2. PubMed ID: 1615342
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Mixed chimerism after allogeneic bone marrow transplantation for leukemias.
    Bertheas MF, Lafage M, Blaise D, Stoppa AM, Viens P, Mannoni P, Maraninchi D.
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():61-3. PubMed ID: 2390641
    [No Abstract] [Full Text] [Related]

  • 38. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients.
    Ringdén O, Pihlstedt P, Markling L, Aschan J, Båryd I, Ljungman P, Lönnqvist B, Tollemar J, Janossy G, Sundberg B.
    Bone Marrow Transplant; 1991 Mar; 7(3):221-6. PubMed ID: 2059758
    [Abstract] [Full Text] [Related]

  • 39. Results of four different protocols for prophylaxis against graft-versus-host disease.
    Tollemar J, Ringdén O, Bäckman L, Janossy G, Lönnqvist B, Markling L, Philstedt P, Sundberg B.
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3008-10. PubMed ID: 2650414
    [No Abstract] [Full Text] [Related]

  • 40. Bone marrow transplantation for leukemia: effects of T lymphocyte depletion of donor bone marrow.
    Champlin R.
    Transplant Proc; 1987 Feb; 19(1 Pt 1):157-9. PubMed ID: 3274769
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.